Compugen Q3 Revenues Drop to $6K as It Plans Cuts | GenomeWeb
NEW YORK (GenomeWeb News) – Compugen today reported that its third-quarter revenues declined to $6,000 from $90,000 year over year, as the firm plans to cut staff and reduce its expenses by 30 percent.
 
The Tel Aviv, Israel-based drug and biomarker discovery platform developer posted a net loss of $3.3 million, or $.12 per share, a 22 percent increase over a net loss of $2.7 million, or $.09 per share, for the third quarter of 2007.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.